Zühlke Ventures AG
VC Fund
Schlieren, Switzerland
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Zühlke Ventures AG invests in
Stages Zühlke Ventures AG invests in
Countries Zühlke Ventures AG invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.1M–$3M
- Series A
- $7M–$11M
Investment Focus
Industry
- Health Care 9 (60%)
- Medical Device 6 (40%)
- Medical 4 (27%)
- Biotechnology 3 (20%)
- Manufacturing 2 (13%)
Stage
- Series A 7 (47%)
- Seed 3 (20%)
- Series B 1 (7%)
- Series C 1 (7%)
- Funding Round 1 (7%)
Country
- Switzerland 10 (67%)
- Sweden 1 (7%)
- United States 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Patrick Griss
Co-Founder & Executive Partner
|
Co-Founder & Executive Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PeriVision
|
Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases. | $3M / Seed / Sep 11, 2025 | |
Bottneuro
|
Bottneuro offers a unique, non-invasive therapy for early- and moderate-stage Alzheimer's Disease patients using electrical stimulations of neurons and glia cells in the brain. Bottoneuro develops stimulation protocols using the NENI technology platform. | $4.3M / Convertible Note / Dec 15, 2022 | |
Indivi
|
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotypinginstruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development. | Series A / Aug 31, 2022 | |
|
Indivi
|
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotypinginstruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development. | Seed / Aug 30, 2022 | |
Evismo
|
Evismo provides diagnostics services in Switzerland | $1.1M / Seed / Sep 14, 2021 | |
|
Evismo
|
Evismo provides diagnostics services in Switzerland | $1.1M / Seed / Sep 14, 2021 | |
Flow Neuroscience
|
Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry. | $10M / Series A / Aug 10, 2021 | |
Koya Medical
|
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy. | $11M / Series A / Jan 14, 2021 | |
Lunaphore
|
Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $7M / Series A / Jul 15, 2017 | |
Swisstom AG
|
Swisstom AG, located in Landquart, Switzerland, develops and manufactures innovative medical devices. Their new lung function monitor enables life-saving treatments for patients in intensive care and during general anesthesia.Unlike traditional tomography, Swisstom´s bedside imaging is based on non-radiating principles: Electrical ImpedanceTomography (EIT). To date, no comparable devices can show such regional organ function continuously and in real-time at the patient’s bedside.Swisstom creates its competitive edge by passionate leadership in non-invasive tomography with the goal to improve individual lives and therapies. | Series C / Jul 17, 2014 | |
| See all 15 investments → | |||
Co-Investors
Business Angels Switzerland (BAS)
2 deals together
DART Ventures
2 deals together
Lichtsteiner Foundation
2 deals together
Swiss Health Angels
2 deals together
Alpana Ventures
1 deal together
Aphelion Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Zühlke Ventures AG invest in?
Zühlke Ventures AG invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Zühlke Ventures AG's check size?
Zühlke Ventures AG typically joins rounds of $1.1M–$3M at Seed and $7M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Zühlke Ventures AG participates in.
How do I contact Zühlke Ventures AG?
Public channels for Zühlke Ventures AG include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zühlke Ventures AG?
The team at Zühlke Ventures AG includes Patrick Griss (Co-Founder & Executive Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
